Bone Biologics (BBLGW) Cash & Equivalents (2016 - 2017)
Bone Biologics (BBLGW) has disclosed Cash & Equivalents for 2 consecutive years, with $1.6 million as the latest value for Q3 2017.
- Quarterly Cash & Equivalents rose 135.67% to $1.6 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2017, up 135.67% year-over-year, with the annual reading at $620375.0 for FY2016, N/A changed from the prior year.
- Cash & Equivalents for Q3 2017 was $1.6 million at Bone Biologics, up from $783014.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $4.2 million in Q1 2016, with the low at $620375.0 in Q4 2016.